Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Mar 28;22(12):3412-7.
doi: 10.3748/wjg.v22.i12.3412.

Two strategies for prevention of cytomegalovirus infections after liver transplantation

Philipp Simon  1 , Max Sasse  1 , Sven Laudi  1 , David Petroff  1 , Michael Bartels  1 , Udo X Kaisers  1 , Sven Bercker  1
Affiliations
Comparative Study

Two strategies for prevention of cytomegalovirus infections after liver transplantation

Philipp Simon et al. World J Gastroenterol. .

Abstract

Aim: To analyze differences in patients' clinical course, we compared two regimes of either preemptive therapy or prophylaxis after liver transplantation.

Methods: This retrospective study was reviewed and approved by the institutional review board of the University of Leipzig. Cytomegalovirus (CMV) prophylaxis with valganciclovir hydrochloride for liver transplant recipients was replaced by a preemptive strategy in October 2009. We retrospectively compared liver transplant recipients 2 years before and after October 2009. During the first period, all patients received valganciclovir daily. During the second period all patients included in the analysis were treated following a preemptive strategy. Outcomes included one year survival and therapeutic intervention due to CMV viremia or infection.

Results: Between 2007 and 2010 n = 226 patients underwent liver transplantation in our center. n = 55 patients were D(+)/R(-) high risk recipients and were excluded from further analysis. A further 43 patients had to be excluded since CMV prophylaxis/preemptive strategy was not followed although there was no clinical reason for the deviation. Of the remaining 128 patients whose data were analyzed, 60 received prophylaxis and 68 were treated following a preemptive strategy. The difference in overall mortality was not significant, nor was it significant for one-year mortality where it was 10% (95%CI: 8%-28%, P = 0.31) higher for the preemptive group. No significant differences in blood count abnormalities or the incidence of sepsis and infections were observed other than CMV. In total, 19 patients (14.7%) received ganciclovir due to CMV viremia and/or infections. Patients who were treated according to the preemptive algorithm had a significantly higher rate risk of therapeutic intervention with ganciclovir [n = 16 (23.5%) vs n = 3 (4.9%), P = 0.003)].

Conclusion: These data suggest that CMV prophylaxis is superior to a preemptive strategy in patients undergoing liver transplantation.

Keywords: Cytomegalovirus; Liver; Preemptive; Prophylaxis; Therapy; Transplantation; Valganciclovir.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival curve. Mortality did not differ significantly between the groups.
See this image and copyright information in PMC

References

    1. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis. 1996;22:537–549. - PubMed
    1. Snydman DR. Epidemiology of infections after solid-organ transplantation. Clin Infect Dis. 2001;33 Suppl 1:S5–S8. - PubMed
    1. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, Kuhr CS, Levy AE, Perkins JD, Reyes JD, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation. 2006;81:1645–1652. - PubMed
    1. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl. 2006;12:112–116. - PubMed
    1. Saliba F, Arulnaden JL, Gugenheim J, Serves C, Samuel D, Bismuth A, Mathieu D, Bismuth H. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc. 1989;21:2260–2262. - PubMed

Publication types

MeSH terms